Nonsmall Cell Lung Cancer Clinical Trial
Official title:
Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the reliable data of third-line treatment for non-small cell lung cancer, the investigators designed a clinical study of antinil hydrochloride versus pemetrexed in maintenance therapy for advanced NSCLC to prospectively evaluate the efficacy of antinil hydrochloride in maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging the survival time of patients with advanced NSCLC, improving the quality of life of patients in the course of treatment, and optimizing treatment strategies to a greater extent.
This study is planned to be carried out in Jiangsu regional multi-center. 83 cases are
preliminarily expected to be included. The study started in December 2018 and ended in
December 2019. It is expected that the trial will end in December 2020.
In the absence of such situations as withdrawal of informed consent, intolerance of drug
toxicity and side effects, or inappropriateness for further trials, each participant's
expected time for research and treatment will continue until radiographically confirmed tumor
progression occurs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06147570 -
A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01312337 -
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Completed |
NCT05860582 -
A Study of [14C]GB491 in Male Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Completed |
NCT02562027 -
SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer
|
N/A | |
| Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02954523 -
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03998189 -
Metabolic and Microbial Profiling of Lung Cancer
|
N/A | |
| Not yet recruiting |
NCT03258671 -
IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer
|
N/A | |
| Recruiting |
NCT03838588 -
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
|
||
| Active, not recruiting |
NCT04984811 -
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
|
Phase 2 | |
| Recruiting |
NCT05688280 -
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02951611 -
Effects of Acupuncture Stimulation on Systemic Inflammation
|
N/A | |
| Recruiting |
NCT02974933 -
Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02980536 -
cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China
|
||
| Completed |
NCT02972216 -
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
|
Phase 4 | |
| Recruiting |
NCT02905591 -
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
|
Phase 2 | |
| Recruiting |
NCT05873439 -
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
|
Early Phase 1 | |
| Active, not recruiting |
NCT02981108 -
A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02299141 -
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 2 |